Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
LYRA vs AVTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AVTX Captures Overall Composite Edge (49.6 HOLD vs 52.2 HOLD), While LYRA Leads 3–2 on Growth & Valuation Pillars
AVTX Overall Winner
6-Pillar Tally: LYRA 3 – 2 AVTX (1 Tie)
Matrix Metrics: LYRA 2 – 5 AVTX
As of Nov 17, 2026, Avalo Therapeutics, Inc. (AVTX) captures the overall head-to-head institutional edge over Lyra Therapeutics, Inc. (LYRA) on higher Unified Composite conviction (49.6/100 HOLD vs. 52.2/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Balance Sheet & Cash Flow), while LYRA wins 3–2 across the 6-pillar growth and valuation breakdown. LYRA trades at $0.49 (N/M Forward P/E, -25032.0% operating margin) versus AVTX at $7.04 (N/M Forward P/E, -161962.7% operating margin).
- Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. AVTX 49.6/100 HOLD), AVTX captures the overall institutional head-to-head verdict (5–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-161962.7% vs. -25032.0% operating margin) and revenue trajectory (-69.3% vs. -87.2% YoY).
- Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile AVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About LYRA vs AVTX
LYRA
Lyra Therapeutics, Inc. Common Stock
$0.49
-62.5% 1D
Market Cap
$2.3M
TTM Revenue
$600,000
Forward P/E
N/M
Beta / 30D Vol
0.33β · 248% Vol
Unified Composite Score
52.2
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
AVTX
Head-to-Head Winner
Avalo Therapeutics, Inc. Common Stock
$7.04
-4.48% 1D
Market Cap
$448.7M
TTM Revenue
$59,000
Forward P/E
N/M
Beta / 30D Vol
1.74β · 164% Vol
Unified Composite Score
49.6
HOLD
Tech 69.0
Fund 65.0
Flow 64.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (LYRA 3 – 2 AVTX)
1. Valuation Multiples
LYRA
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
3.9x
N/M
2. Growth & Scale
AVTX
Revenue Growth (YoY)
-87.2%
-69.3%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$600,000
$59,000
Market Cap
$2.3M
$448.7M
3. Profitability & Quality
LYRA
Gross Margin
N/A
N/A
Operating Margin
-25032.0%
-161962.7%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-404.5%
-33.6%
4. Balance Sheet & Cash Flow
AVTX
Cash Generation (TTM)
-$32M EBITDA
-$63M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
-404.5% ROE
$65M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
LYRA
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
114.2% (22nd %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: LYRA (2) vs AVTX (5)| Institutional Metric | LYRA | AVTX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.3M | $448.7M | AVTX | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -87.2% | -69.3% | AVTX | |
| Operating Margin (TTM) | -25032.0% | -161962.7% | LYRA | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -404.5% | -33.6% | AVTX | |
| 52-Week Range Position | 1% ($0–$38) | 3% ($7–$24) | AVTX | |
| Beta / 30D Volatility | 0.33β · 248% Vol | 1.74β · 164% Vol | AVTX | |
| Unified Institutional Score | 52.2 / 100 (HOLD) | 49.6 / 100 (HOLD) | LYRA | |
| Trailing 12M Revenue (USD) | $600,000 | $59,000 | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.9x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$32M EBITDA (-404.5% ROE) | -$63M ($65M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
AVTX +73.75 pp
3M Horizon
AVTX +69.73 pp
6M Horizon
AVTX +93.16 pp
1Y Horizon
AVTX +93.16 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LYRA Revenue | AVTX Revenue | LYRA Op. Margin | AVTX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $10M | N/A | -503.4% | AVTX |
| FY2019 | N/A | $10M | N/A | -239.1% | AVTX |
| FY2020 | N/A | $10M | N/A | -1087.4% | AVTX |
| FY2021 | $0M | $10M | -15303.5% | -1521.6% | AVTX |
| FY2022 | $0M | $20M | -4131.0% | -207.4% | AVTX |
| FY2023 | $0M | $0M | -4308.1% | -1421.6% | AVTX |
| FY2024 | $0M | $0M | -6280.8% | -15535.6% | LYRA |
| FY2025 | $0M | $0M | -7794.5% | -123601.7% | LYRA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
LYRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
AVTX
BREAKDOWN
Current IV
114.2%
IV Percentile
22nd %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact AVTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
LYRA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
AVTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ LYRA vs AVTX Key Questions & Quantitative Answers
As of Nov 17, 2026, Avalo Therapeutics, Inc. (AVTX) captures the overall head-to-head institutional edge over Lyra Therapeutics, Inc. (LYRA) on higher Unified Composite conviction (49.6/100 HOLD vs. 52.2/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Balance Sheet & Cash Flow), while LYRA wins 3–2 across the 6-pillar growth and valuation breakdown. LYRA trades at $0.49 (N/M Forward P/E, -25032.0% operating margin) versus AVTX at $7.04 (N/M Forward P/E, -161962.7% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. AVTX 49.6/100 HOLD), AVTX captures the overall institutional head-to-head verdict (5–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-161962.7% vs. -25032.0% operating margin) and revenue trajectory (-69.3% vs. -87.2% YoY). Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile AVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AVTX leads the Growth & Scale pillar: LYRA posts -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin), compared with AVTX at -69.3% YoY revenue growth and +0.0% YoY earnings growth on $59,000 TTM revenue (N/A gross margin, -161962.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LYRA cumulative revenue shifted N/A while AVTX shifted +100.0%. In operating R&D and SG&A reinvestment, LYRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVTX.
LYRA screens cheaper on headline valuation multiples. LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin), whereas AVTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LYRA (-404.5% ROE) versus AVTX (-33.6% ROE) capital efficiency.
In options market volatility and institutional positioning, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk). By comparison, AVTX carries 114.2% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.74β · 164% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
AVTX vs LYRA · Reverse Pair
LYRA vs PASG
· Sector Peer
LYRA vs ORIC
· Sector Peer
LYRA vs KROS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking